The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a ...

The popular weight loss drugs are both listed at more than $1,000 per month. The price cut is set for Jan. 1, 2027.

Find insight on WELL Health Technologies, Novo Nordisk and more in the latest Market Talks covering Health Care.

It’s been a topsy-turvy week for Novo Nordisk, makers of the popular weight loss drugs Ozempic and Wegovy. Fresh off the heels of a disappointing trial for one experimental drug, the company has just ...

Drugmaker Novo Nordisk plans to slash list prices for its wildly popular weight-loss and diabetes drugs Wegovy and Ozempic by ...

Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.

These patients, who may have high-deductible health plans or co-insurance, will be able to purchase both the pill and injection forms of obesity treatment Wegovy, the Ozempic diabetes shot, and oral ...

Novo Nordisk announced up to 50% price cuts for Ozempic and Wegovy diabetes and weight-loss drugs starting January 2027, ...

The list price of Wegovy will be cut in half on January 1, 2027, plummeting from around $1,350 to $675 a month. The cost of ...

America’s in the middle of a weight-loss frenzy, driven by blockbuster GLP-1 drugs that have proven very effective at helping adults shed excess pounds. Meanwhile, in what could be another sign of a ...

The reductions will take effect next January, and both Ozempic and Wegovy will list for $675 a month.